Transgenic Platforms
for Antibody Generation

Our proprietary transgenic animals, including OmniRat^®, OmniChicken^® and OmniMouse^® have been genetically engineered to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic^® and OmniClic^® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmnidAb^® is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. The OmniUltra^™ platform, generates naturally optimized human immune antibody repertoires featuring cow-inspired ultralong CDRH3 domains, unlocking novel binding modes and access to challenging targets. OmniUltra also enables the isolation of picobodies^®, the smallest known natural antibody-derived binding domain (4-6 kDa), one-third the size of a nanobody^®. The OmniTaur^™ platform provides cow-inspired antibodies with unique structural characteristics for challenging targets.Our expertise in developing transgenic animal platforms ensures that they have the most flexible options for discovering high-quality antibody leads. We work closely with our partners’ teams to create effective transgenic animal models for human diseases to customize and optimize the process for every campaign. Get in touch with us today to learn more about our full capabilities.

nanobody is a registered trademark of Ablynx NV